Should You Consider Purchasing Bristol Myers Squibb Shares for Their 4.4% Dividend Yield?

Dividend Stocks: A Popular Choice for 2026 Investors

In 2026, many investors have turned their attention to dividend-paying stocks. These investments are attractive not only for the steady income they provide but also for their reputation as relatively secure holdings. Companies that consistently pay dividends typically have robust financial health, which allows them to make regular distributions to shareholders. However, it's important to remember that even these companies are not immune to change, and dividends are never fully guaranteed.

Bristol Myers Squibb: A High-Yield Healthcare Dividend

Bristol Myers Squibb (NYSE: BMY) stands out in the healthcare sector for its generous dividend, currently offering a yield of 4.4%—well above the S&P 500 average of 1.2%. At first glance, this might seem like an obvious pick for income-focused investors. Yet, with looming patent expirations and uncertainties about the company’s future, it’s worth asking whether this stock is as safe as it appears.

Past Performance Doesn’t Guarantee Future Dividends

One common pitfall for dividend investors is relying too heavily on a company’s historical dividend record. Even the most impressive streaks can end, especially if a business faces challenges that require it to redirect cash elsewhere.

Bristol Myers Squibb is approaching a difficult period, with several major drugs—including Eliquis and Opdivo—set to lose patent protection in the near future. As generic competitors enter the market, the company’s revenue could decline, leading to reduced profits and less cash available for dividends. To offset these challenges, Bristol Myers may pursue acquisitions, which could further strain its finances.

In 2023, Bristol Myers’ revenue remained flat at $48.2 billion. For 2024, the company expects sales to fall between $46 billion and $47.5 billion.

Why I’m Looking Elsewhere for Dividend Income

Bristol Myers Squibb has increased its dividend for 17 straight years, maintains a reasonable payout ratio of 72%, and offers an attractive yield. These are all positive signs for dividend investors. However, I’m not adding this stock to my portfolio right now.

The main reason is uncertainty. While a dividend reduction or suspension isn’t certain, it’s a real risk given the company’s current outlook. Although Bristol Myers remains stable for the moment, I don’t feel confident enough to treat it as a “set it and forget it” investment. For me, a good dividend stock should be one you can own without constant worry. Rather than hoping Bristol Myers will maintain its payout, I’d recommend considering a dividend-paying index fund as a more reliable alternative.

Should You Invest in Bristol Myers Squibb Right Now?

Before deciding to buy shares of Bristol Myers Squibb, here’s something to consider:

• The Motley Fool Stock Advisor team recently revealed their picks for the top 10 stocks to buy right now—and Bristol Myers Squibb didn’t make the list. The selected companies have the potential for significant gains in the coming years.
• For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $495,179. Similarly, a $1,000 investment in Nvidia on April 15, 2005, would have grown to $1,058,743.
• Currently, Stock Advisor’s average return stands at 898%, far outpacing the S&P 500’s 183% return. Don’t miss the latest top picks—available exclusively through Stock Advisor—and join a community of investors focused on long-term growth.

*Stock Advisor returns as of March 23, 2026.